Quest Diagnostics (DGX) Develops MCaST Blood Test with MD Anderson Cancer Center

Quest Diagnostics Incorporated (NYSE:DGX) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 10, the company said it is developing a Multi-Cancer Stratification (MCaST) blood test in collaboration with The University of Texas MD Anderson Cancer Center. This initiative aims to improve the assessment of elevated cancer risk in individuals.

The announcement detailed that the MCaST blood test will identify individuals at an elevated risk for various cancers. Afterwards, the individuals will be encouraged to pursue appropriate preventive screenings or other medical evaluations that could lead to earlier detection. The test is designed to identify the risk of developing several cancers, including “colorectal, lung, breast, pancreatic, ovarian, liver, prostate, esophageal, and stomach cancers.”

Quest Diagnostics stated that MCaST, on which the blood test is based, is a “cohesive risk model” developed by Dr. Samir Hanash’s laboratory at MD Anderson Cancer Center. This technology utilizes circulating protein biomarkers, which were identified through “extensive clinical research conducted on screening study cohorts involving tens of thousands of individuals.” The company plans to further refine, develop, and validate this technology for its own laboratory-developed test.

Quest Diagnostics Incorporated (NYSE:DGX) is a major provider of diagnostic testing services. It plays a significant role in the cannabis industry by providing drug testing services. It offers various drug testing methods, including urine, oral fluid (saliva), and hair testing, to detect marijuana use in both workplace and clinical settings.

While we acknowledge the potential of DGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Successful Spin-Off Companies and Their 2025 Returns and 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying.

Disclosure: None. This article is originally published at Insider Monkey.